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An aspartyl protease, Beta-Site APP cleaving enzyme (BACE), was identified as the β-secretase 
responsible for generating the Amyloid β protein that is believed to cause Alzheimer’s disease. 
BACE has a short propeptide domain that is absent in the mature enzyme because of proteolytic 
cleavage after the sequence RLPR. This sequence is a predicted substrate for proprotein 
convertases such as furin. To determine the role of furin and other proprotein convertases, we 
expressed proBACE in a furin-deficient mutant Chinese hamster ovary (CHO-K1) line, RPE.40. 
ProBACE signal was higher in RPE.40 than in the CHO-K1 parent, which confirmed that furin 
plays a role in propeptide removal. However, two independent approaches showed that 
proBACE is cleaved to mature BACE in RPE.40: proBACE was rapidly turned over in RPE.40 
although total BACE was stable, and decanoyl-RVKR-chloromethylketone, an inhibitor of the 
proprotein convertase family, substantially increased proBACE levels in both RPE⋅40 and CHO-
K1. Transient transfection shows that furin, PACE4, PC5/6, and PC7 mediate BACE cleavage in 
vivo, at least when overexpressed. RPE.40 is proficient in BACE activity despite its furin 
deficiency. Therefore, our finding that proBACE is cleaved in this mutant leaves open the 
possibility that maturation is an important regulatory step and a therapeutic target. 
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he 38–43 residue peptide Amyloid β (Aβ), invariably deposited in the Alzheimer’s 
disease (AD) brain, is derived from a larger precursor, Amyloid β protein precursor 
(APP), as summarized below (1–6). Aβ secreted from cultured cells, in the plasma and 
cerebrospinal fluid of normal individuals, is mostly 40 residues (Aβ40), but a small population 
(~10%) is 42–43 residues long (Aβ42) (7–10). Familial AD (FAD) mutations on APP, presenilin 
1 (PS1), and presenilin 2 (PS2) increase levels of Aβ42, making the reduction of Aβ, primarily 
Aβ42, an important therapeutic goal (11). 
 
T 
Aβ is produced by sequential cleavage of APP by proteases named β- and γ-secretases. β-
Secretase cleaves at the amino terminal end of the Aβ sequence, producing a secreted derivative, 
sAPPβ (the N-terminal fragment of APP cleaved before Aβ residue 1) (12) and the Aβ-bearing 
C-terminal fragment of 99 residues, CTFβ (the membrane-anchored C-terminal fragment of APP 
starting at Aβ residue 1) (13). The importance of β-secretase in AD is demonstrated by the 
finding that Aβ and CTFβ levels are specifically increased in the FAD mutant APP derivative 
that replaces KM at residues 670-1 in wild-type APP (APPWT) with NL (APPSW) (14). 
 
A novel pepstatin A-insensitive aspartyl protease, Beta-Site APP cleaving enzyme (BACE), was 
identified as the β-secretase that cleaves at positions 1 and 11 of the Aβ sequence (15–19). 
BACE cleaves APPSW more efficiently than APPWT in vitro, a result that is consistent with the 
higher levels of Aβ and CTFβ generated from cells expressing this mutant APP substrate. A 
homologue of BACE, BACE2, was also found, but this enzyme prefers to cleave within the Aβ 
sequence, making it relevant only in some rare mutant APP forms (20). Protein phosphorylation  
(21) and glycosylphosphatidylinnositol-anchored proteins (22) regulate Aβ biogenesis and β-
secretase processing of APP. An alternative activity, α-secretase, cleaves APP within Aβ 
(between residues 16 and 17) to the larger secreted derivative, sAPPα (the N-terminal fragment 
of APP cleaved before Aβ residue 16) (23) and membrane-associated 83-residue fragment, 
CTFα (the membrane-anchored C-terminal fragment of APP starting at Aβ residue 17) (13). A 
family of disintegrin metalloproteases, such as the tumor necrosis factor alpha converting 
enzyme (TACE) and the Adamalysins, ADAM 10, has been implicated in α-secretase cleavage 
of APP (24–26). The α-secretase pathway is regulated by protein phosphorylation (21). Cleavage 
of CTFβ and CTFα by γ-secretase generates Aβ and a smaller fragment of 24–26 residues called 
P3, respectively. Cleavage by γ-secretase also releases a soluble C-terminal fragment, CTFγ  (the 
soluble C-terminal fragment generated by γ-secretase cleavage after Aβ40/42), although this 
fragment is generally not detected in cell lysates, presumably because of sequestration or rapid 
turnover (27). A combination of several studies indicates that PS1 and PS2 are the active 
subunits of γ-secretase (28–30). Consistent with this notion, knockout animals deficient in PS1 
and PS2 are deficient in γ-secretase activity (31, 32). 
 
Recently, knockout mice lacking BACE were generated, and their viability makes BACE a good 
therapeutic candidate for lowering Aβ in the AD brain. These BACE-deficient mice were 
deficient in Aβ production in the brain and in isolated neurons, a result suggesting that BACE is 
the major β-secretase activity in the brain (33). However, the question of compensation by 
alternative activities that lower Aβ by cleavage within Aβ, for example by BACE2, has not yet 
been examined (20).  
 
The BACE cDNA sequence reveals an integral membrane aspartyl protease with an N-terminal 
signal sequence (residues 1–21) followed by a large luminal catalytic domain, a single 
transmembrane domain (residues 461–477), and a short cytoplasmic domain (residues 478–501). 
However, the purified BACE protein began at residue 46, which indicates that a stretch of basic 
residues (prodomain; residues 22–45) is proteolytically removed in mature BACE (17). Thus, 
proBACE is a zymogen with a 24-residue prodomain whose function has not yet been fully 
characterized. Creemers et al. have suggested that proBACE is active in vivo, making the 
maturation process irrelevant (34). However, this view does not fit the known zymogen 
activation process for other aspartyl proteases and in vitro findings that recombinant proBACE 
shows increased activity when portions of its prodomain were removed by clostripain cleavage 
in vitro (35). One of the fragments starting at residue G59 was threefold more active than 
proBACE (35). A similar threefold increase in BACE activity upon prodomain removal by in 
vitro cleavage at the authentic site, E46, was also recently reported (36). Thus, the enzymes that 
cleave proBACE may be useful therapeutic targets and help us to understand how BACE activity 
is regulated through maturation.  
 
The sequence at the cleavage site for proBACE cleavage is RPLR↓, which follows the rules for 
cleavage by subtilisin-like proprotein convertases that cleave after the recognition motif K/R-Xn-
R, where n = 0, 2, 4, or 6 and X is any amino acid except cysteine (37). However, the sequence 
deviates from the typical cleavage sequence of K/R-X-K/R-R in that it lacks a basic residue in 
the P2 position (38). There are seven known proprotein convertases: furin, PC1/3, PC2, PACE4 
(paired amino acid cleaving enzyme 4), PC4, PC5/6, and PC7. Of these, furin, PACE4, PC5/6, 
and PC7 are most widely expressed in the constitutive secretory pathway (37, 38). Although all 
these enzymes share a similar cleavage-sequence motif, they have distinct substrate preferences. 
For example, LoVo cells that are deficient in furin are incapable of cleaving Newcastle disease 
virus fusion glycoprotein but cleave Human Immunodeficiency Virus envelope protein, GP160, 
as efficiently as normal cell lines (39).  
 
The basis for differences in substrate specificity and the rules for cleavage of specific substrates 
by specific convertases have not yet been determined; therefore, we needed to empirically 
determine the role of each proprotein convertase in the maturation of a proprotein. We used a 
mutant Chinese hamster ovary (CHO-K1) line deficient in furin, RPE.40, to determine the role of 
furin and other convertases in the cleavage of proBACE (40). Extensive analysis has shown that 
both alleles of furin are defective, which results in a furin null phenotype in this cell line (41, 
42). Furin will efficiently cleave both Arg-X-(Lys/Arg)-Arg and Arg-X-X-Arg motifs, whereas 
PACE4 at least prefers substrates with a basic residue in the P2 position (43). Because the 
cleavage site in BACE lacks a basic residue at the P2 position, furin is the likely candidate 
proBACE-processing enzyme. However, the data presented in this study show that proBACE 
maturation does take place in the RPE.40 cell line, which suggests that other activities can 
mediate BACE maturation.  
 




All reagents were from VWR Scientific (West Chester, PA) and were the highest grade available 
unless specified otherwise. The proprotein convertase inhibitor, decanoyl RVKR 
chloromethylketone (d-RVKR-CMK) was from Peptides International (Gaithersburg, MD). 
 
Plasmids and constructs 
 
The BACE cDNA was amplified from a human brain cDNA library (Edge Biosystems, 
Gaithersburg, MD) using the high-fidelity polymerase, PFX (Invitrogen, Carlsbad, CA), and the 
primers: 5’ AGC TCC CTC TCC TGA GAA G and 5’ TCA GTG GTG GTG GTG GTG GTG 
CTT CAG CAG GGA GAT GTC. The amplified cDNA encoding BACE tagged with six-
histidine residues at its C-terminus was cloned into an intermediate vector pTZ18U, subcloned 
into pCDNA3.1zeo (Invitrogen), and confirmed by sequence analysis at the Mayo Clinic 
molecular biology core facility. Furin and PACE4 expressing constructs have been described 
previously (43). PC5/6 and PC7 were obtained by searching the expressed sequence tag 
databases for full-length clones (GenBank: AW412393 and AA104955), purchased from the 
American type culture collection (ATCC) and confirmed by sequence analysis. The PC5/6 and 
PC7 cDNAs were already cloned in pSPORT-derived expression vectors under the human 
cytomegalo-virus early promoter. 
  
Cell culture and transfection 
 
The furin-deficient cell line, RPE.40, was a gift from Dr. Thomas Moehring (University of 
Vermont, Burlington, VT, retired). This cell line is incapable of cleaving Pseudomonas exotoxin 
to its toxic mature form and is deficient in the maturation of several proproteins (40–43, 44, 45). 
The wild-type CHO-K1 parent was from ATCC (CCL-61). CHO-K1 and RPE.40 were 
maintained in OPTI-MEM (Invitrogen), supplemented with 5% fetal bovine serum (FBS; 
HyClone, Logan, UT) and incubated for assays in CCM5 (HyClone). CHO-K1 and RPE.40 were 
transfected with Lipofectamine as described (Invitrogen), and stable cell lines expressing BACE 
(CHO-K1-BACE and RPE.40-BACE) were generated. Where relevant, cells were transiently 
transfected with appropriate plasmids expressing the proprotein convertases under the human 
cytomegalovirus promoter, and cells were collected 48 h after completion of the transfection. To 
avoid the accidental selection of wild-type cells, we tested the RPE.40-BACE cell line for 
sensitivity to Pseudomonas exotoxin. The wild-type CHO-K1 cells were highly sensitive to 
Pseudomonas exotoxin, resulting in complete cell death and its loss from the culture dishes, 
whereas RPE.40-BACE remained resistant as expected for a furin-deficient culture (data not 
shown). CHO-K1, RPE.40, and their transfected derivatives were all similar in growth rate and 




Polyclonal antibodies against PACE4 and PC7 were from Alexis Biologicals (San Diego, CA), 
and antifurin was from Santa Cruz Biotechnology (Santa Cruz, CA). Three rabbit antibodies 
were raised against BACE using peptides derived from the proregion (residues 26–45), the N-
terminal end of the mature protein (residues 46–65), and the C-terminal 15 residues. The 
peptides BACE26-45 C-IRLPLRSGLGGAPLGLRLPR, BACE46-65 
ETDEEPEEPGRRGSFVEMVD-C, and BACECT15 C-RQQHDDFADDISLLK were synthesized 
at the Mayo Clinic protein core facility with terminal cysteine residues as indicated and coupled 
to maleimide-activated keyhole limpet hemocyanin (Pierce, Rockford, IL). Antibodies were 
raised at Cocalico Biologicals (Reamstown, PA) using a custom schedule, and the sera provided 
were tested by Western blot analysis as previously described (46). Antibodies against BACE26-45 
will not detect mature BACE, because the peptide is derived from the proregion of BACE that is 
lost upon proteolytic maturation (Fig. 1). BACE46-65 represents the first 20 residues of mature 
BACE and is against its extracellular domain, and BACECT15 is against the last 15 residues of its 




Transfected RPE.40 cells expressing BACE alone or BACE + furin were seeded into six-well 
dishes at 4 × 105 cells/well and allowed to grow to near confluence for one day. The medium was 
replaced with RPMI lacking cysteine and methionine for 10 min, and cells were incubated for an 
additional 45 min in the same medium containing 200 µCi/well of a mixture of cysteine and 
methionine (Tran35Slabel; ICN; Costa Mesa, CA). The radioactive medium was aspirated and 
replaced with CCM5 for the indicated chase time. Cells were lysed in MPER (Pierce), adjusted 
to RIPA (47), and immunoprecipitated using protein-A beads and a non-immune antiserum to 
reduce background. The supernatant was divided into two parts, precipitated with BACE26-45 and 
BACECT15 in RIPA buffer overnight, and separated on 4–15% polyacrylamide gels (Biorad, 
Richmond, CA). Western blot analyses of media and lysates were conducted and quantified as 
described previously using precast 10% NuPAGE (Invitrogen) or Biorad 4–15% gels (46). All 
quantitative data are based on the analysis of three or more independent samples as previously 
described (22). 
 
RESULTS AND DISCUSSION 
 
BACE propeptide cleavage is reduced in a furin-deficient cell line 
 
Analysis of the BACE protein sequence by Generunner (Hastings Software, Inc., Hastings, NY) 
and PSORT (http://psort.nibb.ac.jp/) reveals a 21-residue signal sequence cleaved by signal 
peptidase in the endoplasmic reticulum (ER). The proBACE protein starting at residue 22 is a 
type-I integral membrane protein with a large extracellular (catalytic) domain, a single 
transmembrane domain, and a short cytoplasmic tail (Fig. 1A). The 24 N-terminal residues are 
post-translationally removed, and the purified mature BACE starts at residue 46 (17). Note that 
immature and mature BACE in the remaining text refer to the proteolytic removal of the 24-
residue prodomain and not its glycosylation states, which are described later. 
 
We transfected CHO-K1 and its furin-deficient derivative, RPE.40, with vector control or BACE 
and analyzed lysates from three independent stable clones by Western blotting with antibodies 
against peptides corresponding to proBACE (BACE26-45) and total (pro + mature) BACE 
(BACE46-65 and BACECT15; Fig. 1). The three antibodies detect a strong BACE band of 75-kDa 
in lysates from transfected RPE.40 and CHO-K1 cell lines (Fig. 1B–D) and a fainter 65-kDa 
band (Fig. 2). Endoglycosidase F (Endo F) deglycosylates both 65- and 75-kDa bands to a single 
50-kDa band, indicating that the two species represent alternative glycosylation states of a single 
protein (Fig. 2). The 65-kDa band is sensitive to endoglycosidase H (Endo H) and therefore 
represents the core glycosylated ER form of BACE, whereas the 75-kDa band is resistant, 
indicating that its N-linked sugars have been elaborated to complex forms after trafficking 
through the secretory pathway. The proBACE signal is stronger in lysates of three independent 
clones from RPE.40 cells than in the parental CHO-K1, although the range of total BACE signal 
detected by BACE46-65 and BACECT15 is similar in the two cell types (Fig. 1B). Thus, BACE 
maturation is reduced in RPE.40 cells, in agreement with previous studies concluding that furin 
is involved in this process (34, 48).  
 
BACE propeptide is cleaved in RPE.40 
 Although BACE cleavage is reduced in RPE.40, we did not observe a reduction in CTFβ or 
secreted Aβ compared with the parental line. Initially, we interpreted this to mean that proBACE 
was active in vivo (34 and our unpublished observations). However, in contrast to our 
expectations, proBACE signal on Western blots was rapidly lost (<1 h) in lysates from  
cycloheximide-treated RPE.40-BACE cells, whereas the total BACE signal remained unchanged 
for up to 8 h (data not shown). These findings argue that BACE maturation continues in the 
mutant RPE.40 cells and are consistent with reports that BACE is a relatively stable protein with 
a half-life of 16 h (49). As indicated in Experimental Procedures, the maturation observed is not 
due to the accidental selection of wild-type cells, because RPE.40-BACE was resistant to 
Pseudomonas exotoxin as expected (40). 
 
To confirm the rapid turnover of proBACE in RPE.40, we conducted a pulse-chase study in 
which transfected RPE.40 cells expressing BACE or co-expressing BACE + furin were 
metabolically labeled with Tran35Slabel for 45 min and chased for 0, 0.5, 1, and 2 h. As expected 
for a glycosylated protein, BACE starts out as the smaller 65-kDa core-glycosylated band at zero 
time of chase that matures into a larger 75-kDa band during the chase (Fig. 3A, B). Both bands 
were precipitated with the BACE26-45 antibody in the RPE.40-BACE cells, but only the 65-kDa 
core glycosylated protein was precipitated in the RPE.40-BACE-furin culture (Fig. 3A). The 
signal of proBACE was reduced after 1 h and almost completely lost after 2 h of chase in 
RPE.40-BACE. The turnover of proBACE was faster in RPE.40-BACE-furin transfected with 
both BACE and furin (Fig. 3A). In contrast, the signal for fully glycosylated BACE increased 
through the duration of the chase (2 h) when immunoprecipitated with BACECT15 (Fig. 3B). The 
rapid turnover of proBACE signal in RPE.40, together with the stability of total BACE, indicates 
that BACE is cleaved in RPE.40-BACE, albeit at a slower rate than in RPE.40-BACE-furin.  
 
To independently show that proBACE is cleaved in RPE.40, CHO-K1-BACE and RPE.40-
BACE were treated for 4 h with an inhibitor of the proprotein convertases, d-RVKR-CMK, and 
lysates were examined for proBACE and mature BACE. With inhibitor treatment, the proBACE 
signal is drastically increased by more than ninefold in the parental CHO-K1 and by more than 
4.5-fold in RPE.40 (Fig. 4A, D). The increase of proBACE signal in the inhibitor-treated cells 
suggests that a proprotein convertase is responsible for the normal loss of the proBACE signal in 
both wild-type and furin-deficient cells. Total BACE signal was not altered by the inhibitor in 
either wild-type CHO-K1 or RPE.40, as shown by Western blotting with BACE46-65 (Fig. 4B, D) 
and BACECT15 (Fig. 4C, D). The large increase in proBACE signal on inhibitor treatment 
indicates that it contributes little to the total BACE signal, allowing us to directly extend the data 
on total BACE to mature BACE. The observed increase of proBACE signal in the furin-deficient 
cell line when treated with a convertase inhibitor—without a similar effect on mature BACE—
suggests that the prodomain continues to be processed in the absence of furin, thereby 
confirming the pulse-chase data (Fig. 3). In addition, the specificity of the inhibitor suggests that, 
in the absence of furin, other proprotein convertases are involved in BACE maturation.  
 
Several known proprotein convertases can cleave BACE to its mature form 
 
Accumulation of proBACE on treatment with brefeldin A, monensin, or A23187 (47 and data 
not shown) and inhibition with d-RVKR-CMK suggests that a calcium-dependent protease, such 
as a proprotein convertase, cleaves proBACE to its mature form in a late Golgi compartment. We 
therefore decided to test whether proBACE levels are reduced in RPE.40 cells transfected with 
furin, PACE4, PC5/6, and PC7, the convertases known to act in the constitutive secretory 
pathway. The data show that proBACE is reduced in cultures transfected with all these 
convertases (Fig. 5A). The levels of proBACE detected by BACE26-45 were significantly lower 
(P<0.05, two-tailed t test) in RPE.40-BACE cells transfected with furin, PC7,  and PC5/6 but 
more modest and not significant for PACE4 (p=0.07), as shown by the graph in Figure 5D. Total 
BACE levels were not reduced by transfection with the proprotein convertases, as detected with 
BACE46-65 (Fig. 5B) or BACECT15 (Fig. 5C) and shown quantitatively in Figure 5D. If anything, 
there was an overall tendency toward an increase in levels with both antibodies (Fig. 5D), but 
this increase was not significant. After transient transfection, we were able to detect furin and 
PC7 expression using commercial antibodies (data not shown). Although good antibodies were 
not available against PACE4 and PC5/6, they should be expressed in the transiently transfected 
cells, as indicated by their ability to reduce the proBACE signal (Fig. 5). In summary, all the 
tested proprotein convertases specifically reduce proBACE signal without simultaneously 
decreasing total BACE (by extension, mature BACE). Thus, in agreement with the previous 
report (34), furin, PC7, PACE4, and PC5/6 appear to augment cleavage of BACE to its mature 
form—at least in transiently transfected cells expressing high levels of these enzymes.   
 
Transfection with PC5/6 reduced levels of the faster, core glycosylated, Endo H-sensitive, 65-
kDa band of proBACE (Fig. 5A) that represents the ER pool of BACE as discussed earlier (Fig. 
2). Because BACE maturation by the convertases should take place primarily in the Golgi, the 
65-kDa band is expected to contain more of the prodomain. Consistent with this prediction, the 
signal of the 65-kDa band detected by the proBACE-specific antibody BACE26-45 (Fig. 5A) is 
higher than with the two antibodies against the mature domains of BACE (Fig. 5B, C). PC5/6 
may at least partly cleave BACE before elaboration of the N-linked sugars, consistent with 
findings that proBACE cleavage starts in early secretory compartments (50).  
 
Tang and co-workers found that furin did not cleave proBACE, but others have demonstrated in 
vitro cleavage of BACE by furin (35, 36, 48). However, proBACE appears to be a poor 
substrate, based on the large amounts of furin needed for its cleavage in vitro (36, 48). In 
addition, the in vitro cleavage by purified furin does not rule out the possibility of contamination 
by another relevant protease, given that the recombinant furin (Affinity Bioreagents Golden, CO) 
was isolated from an animal cell line, BSC-40 (36, 48). Thus, other proprotein convertases may 
be more important players than furin for proBACE processing in vivo. The furin-deficient 
RPE.40 cells are clearly capable of cleaving BACE very efficiently, as observed by the rapid 
turnover of proBACE. It is possible that cleavage may occur at alternative sites in this cell line, 
but this is unlikely because the antibodies BACE26-45 and BACE46-65 used in the study are against 
the few residues adjoining the start of mature BACE. RPE.40 cells expressed PACE4 RNA (43). 
Nevertheless, based on its failure to process several known proprotein convertase substrates, 
these cells do not show detectable PACE4, PC1/2, or PC5/6 activity (J. Sucic, unpublished 
observations). 
 
The identity of the major protease responsible for BACE maturation in RPE.40 cells remains an 
important unanswered question. Based on reports that the major proprotein convertases in CHO-
K1 cells are furin and PC7, the latter is a likely candidate (51). However, given the complexity of 
the proteolytic pathways in the cell, we cannot rule out the possibility that the BACE prodomain 
is cleaved by a protease that is activated by furin and other proprotein convertases. For example, 
membranes from RPE.40 transfected with PACE4 also contain a Ca++ independent protease that 
cleaves HIV GP160 (50). Despite similarities in the substrate specificity of this protease, its lack 
of Ca++ requirement points away from the subtilisin-like proprotein convertases (44).  
 
While this manuscript was in preparation, two J. Biol. Chem. reports in press provided evidence 
for proBACE cleavage by furin (34, 48). One report indicated that the mutant RPE.40 cells are 
deficient in BACE maturation and that β-secretase activity was not reduced in transfected 
RPE.40 cells (34). Although the authors acknowledge the possibility that proBACE may be 
cleaved in RPE.40, they argue against it and suggest that this maturation event is physiologically 
irrelevant (34). Our studies show that, despite the furin deficiency, proBACE is converted to its 
mature form in RPE.40 cells. This result leaves open the possibility that proteolytic cleavage 
regulates β-secretase activity in the AD brain. 
 
The difference in our findings may be due to the method for detection of proBACE (Western 
blotting with a specific proBACE antibody vs. separation of BACE by isoelectric focusing after 
a short label). Ideally, we need a cell line that fails to generate mature BACE to determine 
whether this maturation step is physiologically relevant for regulating β-secretase activity. 
Although peptide inhibitors (e.g., d-RVKR-CMK) of the proprotein convertase pathways are 
known, they are quite unstable, so it is difficult to use them in long-term studies. Given that 
mature BACE is very stable, we need to treat it with inhibitors for long periods to study the 
effects of eliminating it on β-secretase processing in vivo. In addition, these studies cannot really 
be conducted in transfected cells, because proBACE levels are increased by several orders of 
magnitude in transfected cells, which may prevent us from detecting the effect of increasing 
BACE activity by threefold following proteolytic maturation. The finding that proBACE activity 
is 66% lower than mature BACE generated by either furin or clostripain cleavage suggests that 
this pathway is capable of regulating BACE activity in vivo (35, 36). This level of inhibition 
should be physiologically relevant, considering that BACE cleavage of wild-type APP is limiting 
for Aβ production and is the minor pathway for proteolytic processing of APP to secreted 
derivatives. 
 
BACE is expected to be a good therapeutic target based on the viability of knockout mice. 
However, conventional drug screens have not identified a small molecule inhibitor for this 
activity. It has been suggested that it may be difficult to identify a good nonpeptide inhibitor for 
this enzyme with useful bioavailability in the brain (52). The enzymes responsible for cleavage 
of the BACE propeptide may be good drug targets for inhibiting BACE indirectly. In addition, 
proteolytic maturation of proBACE may play an important role in regulating BACE activity in 
the brain as well as in the pathogenesis of AD.  
 
While this manuscript was under review, another paper showing that BACE maturation is 
mediated by several proprotein convertases in vitro was published in the Journal of Biological 
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Figure 1. Three antibodies specifically detect BACE. Panel A is a schematic diagram of BACE, which is a type-1 
integral membrane glycoprotein with a signal sequence (SP; residues 1–21), a short prodomain that is missing in the 
mature protein (PD, residues 22–45), a catalytic luminal domain, a single transmembrane domain, and a short cytoplasmic 
tail. The luminal catalytic domain contains two consensus aspartyl protease motifs and four N-glycosylation sites (not 
shown). Antibodies were raised against selected regions as follows: a1, BACE26-45, PD; a2, BACE46-65, N-terminus of 
catalytic domain; and a3, BACECT15, the C-terminal 15 residues of the cytoplasmic tail. Lysates from untransfected 
control RPE.40 (lanes 1–3) and three independent stable transfectants expressing BACE in RPE.40 (RPE-BACE; lanes 4–
6) and CHO-K1 (CHO-BACE; lanes 7–9) were separated on 10% NuPAGE gels as described in Experimental Procedures. 
Western blotting shows the relative signal of the 75-kDa BACE band detected using antibodies BACE26-45, BACE46-65, and 





Figure 2. BACE is post-translationally modified with N-linked sugars. Equal protein from control (C)-, Endo F (F)-, 
and Endo H (H)-treated lysates of RPE.40-BACE were examined by Western blotting with BACE26-45 (Panel A), BACE46-
65 (Panel B), and BACE CT15 (Panel C). The 75-kDa band is indicated by a dash and the 65-kDa band by an arrowhead on 
the left of each panel. These bands represent the fully glycosylated (75-kDa) and core glycosylated (65-kDa) BACE 
protein. Endo F and Endo H treatment generates a shorter 50-kDa deglycosylated BACE band, indicated by the arrow on 
the right of each panel. The 50-kDa deglycosylated band is more intense than the 65 + 75 kDa bands in the control lanes 
of panels A and B, which suggests that the N-terminal domain detected by the BACE26-45 and BACE46-65 antibodies is 
partially masked by glycosylation. Note that Endo F converts both bands to the 50-kDa deglycosylated form, whereas 





Figure 3. ProBACE is rapidly turned over in RPE.40 cells, but total BACE is stable. A pulse-chase study was 
conducted in RPE.40 cells stably transfected with BACE (RPE.40) and cotransfected with furin (RPE.40-furin) as 
indicated. Immunoprecipitates show turnover of proBACE using BACE26-45 (A) and total BACE using BACECT15 (B). The 
65-kDa core glycosylated band (arrowhead) at 0-time matures into the larger 75-kDa form (dash) after elaboration of 
sugars during the chase period of 0.5–2 h. 
Fig. 4 
 
      
 
Figure 4. A proprotein convertase inhibitor increases proBACE in RPE.40. Transfected CHO-K1 and RPE.40 
cultures expressing BACE were treated with 50-µM d-RVKR-CMK (I) for 4 h at 37ºC and compared with vehicle control 
(C), and BACE was examined by Western blotting with BACE26-45 (Panel A), BACE46-65 (Panel B), and BACECT15 (Panel 
C). Panel D presents the mean ± SD of the 75-kDa band detected by BACE26-45 (gray bars), BACE46-65 (clear bars), and 
BACECT15 (black bars) quantified by densitometry of three independent samples. (*P<0.05 by two-tailed t test.) 
Fig. 5 
 
                    
 
Figure 5. Furin, PC7, PACE4, and PC5/6 increase processing of proBACE in vivo. RPE.40 was transfected with 
vector control (C), furin (F), PC7 (P7), PACE4 (P4), and PC5/6 (P5/6) using Lipofectamine reagent (Invitrogen, Carlsbad, 
CA), as described by the manufacturer. Western blots show proBACE signal detected with BACE26-45 (Panel A). Total 
BACE was detected with BACE46-65 (Panel B) and BACECT15 (Panel C). The dash points to the 75-kDa band and the 
arrowhead to the 65-kDa band. Panel D is a graph showing the quantification of the 75-kDa band from three to six 
independent samples for each condition. Scanned images were quantified as in Figure 4. (*P<0.05 by two-tailed t test.) 
